Skip to: Curated Story Group 1
lifesciencesreview

Advertise

with us

    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Topics
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Business Services
    Business Services
    Business Services
    Business Services
    Business Services
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Pharmacy Management
    Regulatory Services
  • CXO Insights
  • Vendor Viewpoint
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • CXO Awards
SEPTEMBER 2024LIFE SCIENCES REVIEW8MAKING THE COMPLEX LOOK SIMPLEBy Tony Street, Managing Director, OrifarmTony StreetMIN MY OPINIONIN MY OPINIONore than ever, significant macro-economic and geopolitical challenges push the clinical development industry to deliver more with less.Following two years of COVID-19 studies having priority status with competent authorities, sponsor companies, and service providers, coupled with conflict in Ukraine and Russia, two countries that provide a large patient population for clinical trials, we are now seeing healthcare systems and the clinical trials industry playing "catch up" in an increasingly competitive landscape. Trial sponsor companies determinedly compete for patients, vendor resources, and commercial pharmaceutical products to be used as comparators and co-medications in clinical trials.As a clinical trial sponsor, ensuring your study is attractive to patients and study sites is essential for achieving recruitment goals.For the clinical supplies industry, this requires us to provide a reliable, high-quality supply chain, minimizing the hassle factor for study sites and patients, while at the same time achieving the optimal balance between a lean and waste-free supply chain, supply continuity, and costs of distribution.Tackling the challenging clinical trial supply forecastsForecasting clinical trial supply is notoriously challenging. Despite the multitude of forecasting and simulation tools now available on the market, a lack of robust input data often results in forecasts that are unreliable. To counter the fluctuating levels of demand and ensure all patients receive the right product at the right time, the pharma and biopharma industries have traditionally been ready to sacrifice a lean supply chain, with some sponsors reporting that up to 65­80 percent of products manufactured or procured for clinical trials are never administered to patients.Sourcing of commercial products for use as comparators and co-medication will ordinarily be undertaken via either a "direct to manufacturer" approach or by sourcing stock "out of market" via wholesalers. Products sourced directly from a manufacturer can provide batch size guarantees and paperwork such as
< Page 7 | Page 9 >